SEC Form 4 reporting owner

Cheng Sohanya Roshan

Cheng Sohanya Roshan has filed 4 Form 4 transactions reported between January 31, 2026 and May 14, 2026, as EVP & Chief Commercial Officer of Karyopharm Therapeutics Inc..

Name as filed: Cheng Sohanya Roshan

Open-market buys, 24 mo
None
reported
Open-market sales, 24 mo
$46K
2 lines
Companies
1
with Form 4 filings
Latest transaction
May 14, 2026
transaction date

Roles and reported holdings

  • KPTIKaryopharm Therapeutics Inc.
    Jan 31, 2026 – May 14, 2026

    EVP & Chief Commercial Officer

    Held directly107,940 sh as of May 14, 2026 · Form 4

    24 months: $46K sold

Transaction history

All 4 reported transactions, newest first. Every row links to the Form 4 on SEC EDGAR.

DateCompanyTypeSharesValueFiling
May 14, 2026KPTIEVP & Chief Commercial OfficerOpen-market saleCode S · direct324$3K@ $9.50Form 4
May 13, 2026KPTIEVP & Chief Commercial OfficerGrant or awardCode A · direct947—Form 4
Mar 2, 2026KPTIEVP & Chief Commercial OfficerOpen-market saleCode S · direct4,604$43K@ $9.41Form 4
Jan 31, 2026KPTIEVP & Chief Commercial OfficerGrant or awardCode A · direct32,415—Form 4

How this page is built

Every row comes from a Form 4 filed with the SEC, which officers, directors and holders of more than 10% of a company’s stock must file within two business days of a trade. Transactions are grouped by the reporting owner’s name as filed (spacing, capitals and punctuation ignored); two different people filing under an identical name would appear together, and one person filing under two spellings appears on two pages.

Open-market totals count code P purchases and code S sales over the last 24 months. The same trade reported on more than one filing is counted once; when another owner (for example a fund and its general partner) reports the identical trade, they are listed beside it. Holdings are the shares owned after the latest purchase, sale, gift or tax-withholding line, shown separately for direct and indirect ownership; an indirect figure is one holding line, not a total across every trust or entity.

This page describes what was filed with the SEC; it is not investment advice or a recommendation to buy or sell any security.